TCR2 Therapeutics Inc. (NASDAQ:TCRR)’s traded shares stood at 2.11 million during the last session. At the last check today, the stock’s price was $10.94, to imply a decrease of -30.38% or -$4.78 in intraday trading. The TCRR share’s 52-week high remains $35.86, putting it -227.79% down since that peak but still an impressive -11.06% since price per share fell to its 52-week low of $12.15. The company has a valuation of $604.12M, with an average of 0.52 million shares in intraday trading volume over the past 10 days and average of 366.07K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for TCR2 Therapeutics Inc. (TCRR), translating to a mean rating of 1.70. Of 9 analyst(s) looking at the stock, 0 analyst(s) give TCRR a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 9 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.65.
TCR2 Therapeutics Inc. (NASDAQ:TCRR) trade information
After registering a -30.38% downside in the latest session, TCR2 Therapeutics Inc. (TCRR) has traded red over the past five days. The stock hit a weekly high of 19.03 this Thursday, 09/16/21, dropping -30.38% in its intraday price action. The 5-day price performance for the stock is -13.63%, and 4.66% over 30 days. With these gigs, the year-to-date price performance is -49.18%. Short interest in TCR2 Therapeutics Inc. (NASDAQ:TCRR) saw shorts transact 2.72 million shares and set a 8.29 days time to cover.
Analysts on Wall Street suggest a consensus price target of $39.67, implying an increase of 72.42% to the stock’s recent value. The extremes give us $28.00 and $51.00 for target low and target high price respectively. As such, TCRR has been trading -366.18% off suggested target high and -155.94% from its likely low.
TCR2 Therapeutics Inc. (TCRR) estimates and forecasts
Looking at statistics comparing TCR2 Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. TCR2 Therapeutics Inc. (TCRR) shares are -33.25% down over the last 6 months, with its year-to-date growth rate lower than industry average at -8.75% against 18.10%. Revenue is forecast to shrink -16.10% this quarter before falling -32.70% for the next one.
TCR2 Therapeutics Inc. has its next earnings report out between August 10 and August 16. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. TCR2 Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
TCR2 Therapeutics Inc. (NASDAQ:TCRR)’s Major holders
TCR2 Therapeutics Inc. insiders hold 1.29% of total outstanding shares, with institutional holders owning 103.33% of the shares at 104.68% float percentage. In total, 103.33% institutions holds shares in the company, led by Wellington Management Group, LLP. As of Jun 29, 2021, the company held over 5.33 million shares (or 13.97% of shares), all amounting to roughly $87.54 million.
The next major institution holding the largest number of shares is MPM Asset Management, LLC with 4.05 million shares, or about 10.61% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $66.47 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the TCR2 Therapeutics Inc. (TCRR) shares. Going by data provided on Jun 29, 2021, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 1.7 million shares. This is just over 4.46% of the total shares, with a market valuation of $27.96 million. Data from the same date shows that the other fund manager holds a little less at 0.75 million, or 1.97% of the shares, all valued at about 12.32 million.